Teva Expects 180-Day Generic Exclusivity On Three Pravachol Doses
This article was originally published in The Pink Sheet Daily
Executive Summary
Teva expects to receive 180-day generic marketing exclusivity on three of the four dosage strengths of Bristol-Myers Squibb's Pravachol (pravastatin)
You may also be interested in...
Teva Loses Pravachol Exclusivity Period; Multiple Generics To Launch In 2006
FDA tells Teva that the 180-day exclusivity period for three pravastatin doses expired in February. As a result, as many as six companies – including Teva – could be in a position to launch generic Pravachol when Bristol’s composition of matter patent expires in April 2006. Teva plans to sue FDA to reinstate its first-to-file exclusivity period.
Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing
Commissioner Robert Califf discussed the agency’s request for $12.3m to address shortages and legislation to require that manufacturers provide more detailed information about increased demand and supply chain vulnerabilities.